Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou

Dengue Fever Clinical Trial

Official title:

Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02608047
• Other study ID #: 201508020263
• Status: Recruiting
• Phase: N/A
• First received: October 11, 2015
• Last updated: November 17, 2015
• Start date: October 2014
• Est. completion date: October 2017

Study information

• Verified date: November 2015
• Source: Guangzhou 8th People's Hospital
• Contact: Fuchun Zhang, doctor
• Phone: 8620-83710219
• Email: gz8hzfc[@]126.com
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to elucidate the local epidemic problem and epidemiological characters of dengue fever in Guangzhou, to establish diagnostic and treatment standard and clinical treatment system of severe cases to reduce the morbidity and mortality of dengue fever.

Description:

To study the epidemiological and pathogenic of dengue virus in Guangzhou, which help to reveal the regular prevalent pattern and the natural epidemic focus of dengue fever. To establish dengue virus sequence database of Guangzhou region, research the biological characteristics and molecular characteristics of dengue fever epidemic strains especially in 2014 in Guangzhou region, to determine the source and variation of this epidemic strains , which finally help to reveal the cause of the pandemic.

To investigate the serum epidemiology of 7800 large groups of people in 12 county-level cities in Guangzhou by stratified random sampling method. It will enrich the research database of the dengue fever serological antibody level survey of people in Guangzhou. After that the investigators could provide a scientific reference for setting up a risk evaluation and implementation of targeted control measures, and also provide reference for analysis of the epidemic situation in other areas.

To study on molecular markers predictive of severe dengue fever and protective immunity after dengue virus infection. The investigators will obtain both serotype-specific and cross-reactive antibodies, which is highly protective neutralizing antibodies. Then the investigators will explore the potential for clinical application about these neutralizing antibodies. The dengue virus were sequenced which caused dengue fever or severe dengue fever in 2014, and do bioinformatics analysis to find the genetic loci which may be responsible for virulence of dengue virus.

To sum up the clinical and laboratory data of dengue fever in 2014, to carry out the research on the diagnosis and treatment of dengue fever, to explore the effectiveness, safety and mechanism of Integrated Chinese and Western medicine treatment for dengue fever patients，to establish of a more perfect system for the diagnosis and treatment of dengue fever in China.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: October 2017
• Est. primary completion date: October 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Dengue patients confirmed by dengue virus NS1 or RNA

Exclusion Criteria:

• Pregnant women

• Fever diseases caused by other viruses

• Combined bacterial infection

• Without complications such as diabetes and tumor.

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Dengue
• Dengue Fever
• Fever

Locations

Country	Name	City	State
China	Guangzhou NO 8. people's hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Guangzhou 8th People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All cause severe dengue		One year	No